4.78
+0.07(+1.49%)
Currency In USD
| Previous Close | 4.71 |
| Open | 4.69 |
| Day High | 5.09 |
| Day Low | 4.69 |
| 52-Week High | 68.7 |
| 52-Week Low | 4.36 |
| Volume | 128,280 |
| Average Volume | 471,529 |
| Market Cap | 12.8M |
| PE | -0.25 |
| EPS | -18.9 |
| Moving Average 50 Days | 7.54 |
| Moving Average 200 Days | 18.51 |
| Change | 0.07 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.05 as of July 31, 2025 at a share price of $4.78. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $10.55 as of July 31, 2025 at a share price of $4.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
GlobeNewswire Inc.
Jul 02, 2025 8:15 PM GMT
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today a
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
GlobeNewswire Inc.
Jul 01, 2025 1:25 PM GMT
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today a
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
GlobeNewswire Inc.
Jun 26, 2025 12:05 PM GMT
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY,